Perspective Therapeutics, Inc. (CATX)

USD 2.97

(-3.26%)

Market Cap (In USD)

200.73 Million

Revenue (In USD)

7.1 Million

Net Income (In USD)

-14.67 Million

Avg. Volume

923.91 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.94-19.1
PE
-
EPS
-
Beta Value
1.467
ISIN
US46489V1044
CUSIP
-
CIK
728387
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Johan M. Spoor
Employee Count
-
Website
https://www.perspectivetherapeutics.com
Ipo Date
2005-11-10
Details
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.